SFROWASA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Sfrowasa, and when can generic versions of Sfrowasa launch?

Sfrowasa is a drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in SFROWASA is mesalamine. There are twenty-eight drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sfrowasa

A generic version of SFROWASA was approved as mesalamine by PADAGIS ISRAEL on September 17^th, 2004.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SFROWASA?
What are the global sales for SFROWASA?
What is Average Wholesale Price for SFROWASA?

Summary for SFROWASA

International Patents:	7
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	181
Patent Applications:	4,191
Drug Prices:	Drug price information for SFROWASA
What excipients (inactive ingredients) are in SFROWASA?	SFROWASA excipients list
DailyMed Link:	SFROWASA at DailyMed

Drug patent expirations by year for SFROWASA

Pharmacology for SFROWASA

Drug Class	Aminosalicylate

US Patents and Regulatory Information for SFROWASA

SFROWASA is protected by one US patents.

Patents protecting SFROWASA

Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Speciality Lp	SFROWASA	mesalamine	ENEMA;RECTAL	019618-002	Jun 20, 2008	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for SFROWASA

See the table below for patents covering SFROWASA around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
New Zealand	578674	REDUCED IRRITANT ENEMA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD)	⤷ Sign Up
Canada	2677095	LAVEMENT AMELIORE A EFFET IRRITANT REDUIT DESTINE AU TRAITEMENT D'UNE AFFECTION INTESTINALE INFLAMMATOIRE (IBD) (IMPROVED REDUCED IRRITANT ENEMA FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (IBD))	⤷ Sign Up
Denmark	2107870		⤷ Sign Up
European Patent Office	0279093	CONTAINER FOR A STABILIZED AQUEOUS SOLUTION OF 5-AMINOSALICYLIC ACID	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for SFROWASA

Pharmacology for SFROWASA

Patents protecting SFROWASA

Make Better Decisions: Try a trial or see plans & pricing